Publications

Abstract Comprehensive immunological profiles have not been studied in relation to methamphetamine (MA) use, MA dependency, or MA-induced psychosis (MAP). Using the BioPlex Pro Human Cytokine 48-Plex panel, this study measured M1 macrophage, T helper (Th)-1, Th-2, growth factor, and chemokine profiles, as well as the immune inflammatory response system (IRS) and compensatory immunoregulatory system (CIRS) in peripheral blood samples from patients with MA use (n=51), MA dependence (n=47), and MAP (n=43) in comparison with healthy controls (n=43). We discovered that persistent MA use had a robust dose-dependent suppressive impact on all immunological profiles, suggesting extensive immunosuppression. The most reliable biomarker profile of MA use is the combination of substantial CIRS suppression and a rise in selected pro-inflammatory cytokines, namely CCL27 (CTACK), CCL11 (eotaxin), and interleukin (IL)-1α. In addition, MA dependency is related with a more severe immunosuppression, as demonstrated by lower stem cell factor and higher IL-10 levels. MAP is related with a significant decrease in all immunological profiles, particularly CIRS, and an increase in CCL5 (RANTES), IL-1α, and IL-12p70 signaling. In conclusion, long-term MA use and dependency severely undermine immune homeostasis. This results in widespread immunosuppression, which may increase the likelihood of infectious and immune illness or exacerbate disorders such as hepatitis and AIDS. Elevated levels of CCL5, CCL11, CCL27, IL-1α, and/or IL-12p70 may be associated with severe peripheral (atherosclerosis, cutaneous inflammation, immune aberrations, hypospermatogenesis) and central (neuroinflammation, neurotoxic, neurodegenerative, depression, anxiety and psychosis) side effects. Our message: “cease using MA, or better yet, never begin using MA”.

Purpose Lowered thiol (-SH) groups and glutathione (GSH) metabolism may be associated with prostate cancer (PCa) and benign prostatic hyperplasia (BPH). The objectives of this study were to systematically review and meta-analyze the associations among -SH groups, GSH, GSH peroxidase (GPx), GSH reductase (GR), and GSH transferase (GST) and PCa/BPH.Methods Four electronic databases were searched for studies that reported -SH and GSH variables in PCa/BPH and healthy controls (HC) and the data were meta-analyzed by calculating Hedges’s g with 95% confidence intervals.Results Twenty studies were included in this meta-analysis. Total -SH (g = −1.750, −2.341/−1.159), GPx (g = −0.789, −1.234/−0.344), GSH (g = −2.219, −4.132/−0.305), and the combination of -SH, GPx, and GSH (g = −1.271, −1.271/−0.800) were significantly lower in PCa patients than in HC. -SH (g = −1.752, −3.123/−0.381) and the combination of -SH, GPx, and GSH (g = −0.813, −1.298/−0.327) were significantly lower in BPH patients than in HC. GPx was significantly lower in PCa than in BPH patients (g = −0.455, −0.896/−0.014). Heterogeneity levels were very high, but Egger’s test showed that none of the biomarkers showed significant publication bias.Conclusion Thiol/GPx antioxidant defenses are significantly attenuated in patients with PCa while patients with BPH occupy an intermediate risk group position between PCa patients and HC.

(1) Background: Activated immune-inflammatory pathways play an important role in the pathogenesis of depression and pathological obesity. Obesity might promote production of cytokine interleukin 17, which plays a significant role in neuro-immune reactions. The study aimed at assessing the relationship between Body Mass Index (BMI) and IL-17 expression, taking into account the clinical psychiatric variables in patients with depression. (2) Methods: A total of 125 participants took part in the study (95 depressed patients, 30 healthy controls). Data concerning the course of depressive disorders and BMI were collected. The severity of depressive symptoms was assessed using the Hamilton Depression Rating Scale (HDRS). Reverse transcription polymerase chain reaction (RT-PCR) was used to assess IL-17 gene expression at the mRNA levels, while enzyme-linked immunosorbent assay (ELISA) was used to assess IL-17 expression at the protein level. (3) Results: Patients with more hospitalizations showed significantly higher IL-17 mRNA expression levels and higher BMI. However, no correlation between BMI and IL-17 expression was found in depressed patients. (4) Conclusions: Our study revealed that BMI does not affect IL-17 expression in patients with depression. However, further studies should be conducted to evaluate the effects of IL-17 inhibition on adipose tissue and vice versa.

Abstract Autobiographical memory (AM) dysfunction has been proposed as a neurocognitive mechanism underlying the development and maintenance of depression. However, case–control neuroimaging studies investigating the neural correlates of AM in depression have yielded inconsistent findings. The present study utilized neuroimaging meta-analyses to identify robust neural markers of AM dysfunction in depression and characterize the associated behavioral and network-level mechanisms. A preregistered neuroimaging meta-analysis ( https://osf.io/35xtf ) was conducted, incorporating data from 341 patients with unipolar depression, 82 individuals at risk of depression, and 261 healthy controls across case–control functional magnetic resonance imaging studies examining AM processing. Meta-analytic network-level and behavioral decoding analyses were performed to aid interpretation of the findings. Compared with controls, the depression group displayed increased activation in the right paracingulate cortex (dorsal anterior cingulate [dACC]) and precuneus, and decreased activation in the anterior insula during AM recall. Exploratory valence-specific analyses revealed that negative AM recall was associated with increased activity the dACC and precuneus. Meta-analytic decoding linked the dACC to the salience network and to domains related to negative affect and executive control, while the precuneus was associated with the default mode network and with processes related to social cognition and AM. Findings do not support prevailing models emphasizing altered amygdala and hippocampal function in AM deficits in depression. Instead, they highlight the involvement of core regions within the salience and default mode networks as key neural substrates of AM dysfunction. These regions may contribute to affective, social-cognitive, and mnemonic disturbances that shape the valence-specific nature of AM deficits in depression.

We examine the relationship between nicotine dependence (ND) and ND-related medical disease and polymorphisms by deletion in genes that encode glutathione S-transferases (GSTs), e.g. GSTM1 and GSTT1. Individuals with homozygous gene deletions show deficiencies in GSTs enzyme activities impairing detoxification.This study comprised 182 tobacco users and 182 controls (neversmokers). GSTM1 and GSTT1 polymorphisms were assessed using a Multiplex- PCR based protocol.Logistic regression analyses showed a significant association between ND and the GSTM1 and GSTT1 null genotypes. There were no significant associations between GSTT1, GSTM1 and GSTT1/M1 genetic variants and the Fagerström test for ND, age at onset, smoking cessation or a family history of ND. Patients with ND had increased rates of a family ND history and an increased prevalence of cardiovascular disease, hypertension, and lung disease. The null genotypes were associated with hypertension (i.e. GSTT1 × ND interaction), diabetes type 2 (i.e. GSTM1 × GSTT1 interaction), lung disease (i.e. GSTM1 × ND interaction) and cancer (i.e. GSTT1). The results show that GST null genotypes may confer protection against ND while they increase risk towards ND-related medical disorders.

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Although previously restricted to a limited number of medical conditions, there is a growing appreciation that 'autoimmune' (or immune-mediated) processes are important aspects of a wide array of diverse medical conditions, including cancers, neurodegenerative diseases and psychiatric disorders. All of these classes of medical conditions are associated with alterations in mitochondrial function across an array of diverse cell types. Accumulating data indicate the presence of the mitochondrial melatonergic pathway in possibly all body cells, with important consequences for pathways crucial in driving CD8+ T cell and B-cell 'autoimmune'-linked processes. Melatonin suppression coupled with the upregulation of oxidative stress suppress PTEN-induced kinase 1 (PINK1)/parkin-driven mitophagy, raising the levels of the major histocompatibility complex (MHC)-1, which underpins the chemoattraction of CD8+ T cells and the activation of antibody-producing B-cells. Many factors and processes closely associated with autoimmunity, including gut microbiome/permeability, circadian rhythms, aging, the aryl hydrocarbon receptor, brain-derived neurotrophic factor (BDNF) and its receptor tyrosine receptor kinase B (TrkB) all interact with the mitochondrial melatonergic pathway. A number of future research directions and novel treatment implications are indicated for this wide collection of poorly conceptualized and treated medical presentations. It is proposed that the etiology of many 'autoimmune'/'immune-mediated' disorders should be conceptualized as significantly determined by mitochondrial dysregulation, with alterations in the mitochondrial melatonergic pathway being an important aspect of these pathoetiologies.